MGX
Metagenomi, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website metagenomi.co
- Employees(FY) 223
- ISIN US59102M1045
Performance
+1.6%
1W
-15.36%
1M
-42.62%
3M
-32.1%
6M
-32.1%
YTD
-32.1%
1Y
Profile
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Investment Analysis Report: MGX
Overview
MGX is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $457,837,879. In this report, we will conduct a detailed analysis of MGX's financial health, earnings and revenue growth, profitability, operating mar...
Technical Analysis of MGX 2024-05-10
Overview:
In analyzing the technical indicators for MGX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
-
...
Recent News & Updates
- 2024-05-14 10:54
- 2024-05-14 04:05
- 2024-05-03 22:49
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript(Insidermonkey)
- 2024-05-01 18:04
- 2024-05-01 04:00
- 2024-05-01 01:53
- 2024-04-07 20:00
Metagenomi to Present at Upcoming Scientific Meetings(Globenewswire)
- 2024-03-26 21:16
- 2024-02-29 03:30
- 2024-02-16 06:24
Daily – Vickers Top Buyers & Sellers for 02/16/2024(Argus Research)
- 2024-02-13 16:35
Metagenomi Announces Closing of Initial Public Offering(GlobeNewswire)
- 2024-02-13 03:35
Metagenomi Announces Closing of Initial Public Offering(Globenewswire)
- 2024-02-08 22:16
Metagenomi Announces Pricing of Initial Public Offering(GlobeNewswire)
- 2024-02-08 09:16
Metagenomi Announces Pricing of Initial Public Offering(Globenewswire)
Page 1 of 1
previousnext